•  
  •  
  •  
  •  

2026-07-19 23:38:47

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Punjab National Bank Scripting Financial Excellence: Net Profit Skyrockets 213.6% in Q1 FY27 Driven by Asset Quality Milestones and Digital Edge
  • Axis Bank Group Delivers Stellar Q1 FY27 Performance: Consolidated Net Profit Climbs to ₹7,632 Crore and Advances Surge 19% Y-o-Y
  • Reliance Industries Starts New Fiscal on a High: Q1 FY27 Revenue Surges 24.5% to ₹3.4 Lakh Crore as Jio and O2C Units Drive Record Earnings
  • Chembond Material Technologies Consolidated Net Profit Surges 43.5% to ₹572.6 Lakh in Q1 FY27; Revenue Tops ₹7,200 Lakh
  • Tata Technologies Q1 FY27 Results: Net Income Surges to ₹181 Crore Fueled by Blockbuster $100 Million Tenneco Deal and Global Automotive Wins

Keywords Selected:  StridesPharmaScience

Stock Report

  • Strides Partners with Ascent Capital to Unlock Value in Pivot Path
  • Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz
  • Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
  • Strides Pharma Science Ltd consolidated Q2FY26 net profit climbs to Rs. 127.53 crores
  • Strides and Incepta Partner to Expand Women's Health Access with WHO-Prequalified Contraceptive
  • Strides Pharma Science Ltd consolidated Q1FY26 profit at Rs. 99.60 crores
  • Strides strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg
  • Strides acquires identified ANDAs from Nostrum Laboratories, Inc., USA
  • Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets, 125 mg /250 mg, Expanding the Existing OTC Portfolio
  • Strides Pharma Science Ltd reports consolidated net profit of Rs. 93.23 crores in Q2 FY2025
  • OneSource receives equity commitments of INR 8,010 mn from marquee investors at a pre-money equity valuation of USD 1.65 bn
  • Strides receives USFDA approval for Fluoxetine Tabs 60 mg
  • Strides announces approval from Equity Shareholders and Secured Creditors for creation of OneSource - India's first Specialty Pharma CDMO
  • Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg
  • Strides Pharma Science Ltd gets EIR from USFDA on continued GMP status for the facility in Alathur, Chennai
  • Strides Pharma Science Ltd Q1 FY2024-25 net profit rises to Rs. 70.20 crores
  • Strides receives USFDA approval for Sevelamer Carbonate Tablets, 800 mg
  • Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg
  • Strides receives USFDA approval for Gabapentin Tablets USP, 600 mg and 800 mg
  • Strides receives USFDA approval for Pregabalin Capsules
  • Stelis Biopharma updates on receipt of consideration from Syngene
  • Strides Pharma Science Ltd provided corporate guarantee to Trinity Pharma Proprietary Ltd's borrowing
  • Stelis Biopharma announces closure of its transaction with Syngene International Ltd
  • Strides launches Icosapent Ethyl Acid Soft Gel Capsules in partnership with Amneal

Latest Post

  • Punjab National Bank Scripting Financial Excellence: Net Profit Skyrockets 213.6% in Q1 FY27 Driven by Asset Quality Milestones and Digital Edge
  • Axis Bank Group Delivers Stellar Q1 FY27 Performance: Consolidated Net Profit Climbs to ₹7,632 Crore and Advances Surge 19% Y-o-Y
  • Reliance Industries Starts New Fiscal on a High: Q1 FY27 Revenue Surges 24.5% to ₹3.4 Lakh Crore as Jio and O2C Units Drive Record Earnings
  • Chembond Material Technologies Consolidated Net Profit Surges 43.5% to ₹572.6 Lakh in Q1 FY27; Revenue Tops ₹7,200 Lakh
  • Tata Technologies Q1 FY27 Results: Net Income Surges to ₹181 Crore Fueled by Blockbuster $100 Million Tenneco Deal and Global Automotive Wins


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025